Use of a Multitarget Fluorescence In Situ Hybridization Assay to Diagnose Bladder Cancer in Patients With Hematuria

Sarosdy, Michael F.; Kahn, Paul R.; Ziffer, Mark D.; Love, William R.; Barkin, Jack; Abara, Emmanuel O.; Jansz, Ken; Bridge, Julia A.; Johansson, Sonny L.; Persons, Diane L.; Gibson, Jane

doi:10.1016/s0022-5347(06)00576-3

Cited by 107 publications

(82 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The UroVysion™ FISH assay has been increasingly used as a valuable adjunct in detecting and monitoring bladder cancer, not only in cytologically negative, but also in cytologically inconclusive urine samples [5]. Recently, the UroVysion™ assay for detecting bladder cancer in patients evaluated for gross or microscopic hematuria was also approved by the FDA [6]. Similar to UroVysion FISH probes design, probes specific for centromeres of chromosomes 3, 7, 17 and for the p16 (9p21) locus were used in our study.…”

Section: Discussionmentioning

confidence: 99%

“…Although a number of probes have been investigated to determine which combination yields the highest sensitivity and specificity for TCC detection, the optimal combination was found to combine CEPs for chromosomes 3, 7, and 17, with a LSI probe to the 9p21 band. This combination significantly increased both the sensitivity and specificity of the assay compared with single probe analysis [5,6,12,13].…”

Section: Discussionmentioning

confidence: 99%

“…Early studies demonstrated that multitarget fluorescence in situ hybridization (FISH) analysis for aneuploidy of chromosomes 3, 7 and 17, and loss of the 9p21 locus provided high sensitivity and specificity in the detection of bladder TCC in patients with negative urine cytology and gross or microscopic hematuria [5,6]. It has been reported that abnormal karyotypes in UUT-TCC are similar to those found in bladder TCC [7].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology

Huang¹,

Li²,

Pang³

et al. 2012

neo

View full text Add to dashboard Cite

We evaluated the performance of a multiprobe FISH (fluorescence in situ hybridization) assay for noninvasive detection of upper urinary tract transitional cell carcinoma (UUT-TCC) in patients with asymptomatic hematuria and negative urine cytology. Voided urine samples from 285 patients with asymptomatic hematuria and negative urine cytology were prospectively analyzed by FISH technique. FISH assays were performed to detect chromosomal changes frequently associated with TCC, including aneuploidy of chromosomes 3, 7 and 17, and loss of the 9p21 locus. Eleven (3.9%) had a positive FISH result. Of the 11 patients, nine (81.8%) were found to have a TCC of the upper urinary tract, while no patients with negative FISH findings were found to have UUT-TCC. In this selected cohort, the sensitivity and specificity of FISH for the detection of UUT-TCC was 100% and 99.3%, respectively. Our preliminary data suggest that the clinical utility of FISH assay of chromosomes 3, 7, 9, and 17 as a noninvasive ancillary test for the diagnosis of UUT-TCC in a selected patient population with asymptomatic hematuria and negative urine cytology and by significant high sensitivity and specificity may be a reliable diagnostic approach for early detection of UUT-TCC patients. Further larger prospective and multicenter trials are needed to confirm our results.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology

Huang¹,

Li²,

Pang³

et al. 2012

neo

View full text Add to dashboard Cite

show abstract

“…[34,35] Notably, the US Food and Drug Administration has actually approved the use of FISH (UroVysion-Abbott Molecular Inc) for urothelial cancer screening for hematuria and surveillance in known bladder cancer patients. [36] Nevertheless, compared to urine cytology, the routine use of UroVysion is still debatable; this test is a costly method to diagnose clinically insignificant low-grade bladder tumors. [37,38] In addition, the false positive rate related to the presence of benign urothelial umbrella cells with abnormal DNA ploidy makes the routine use of UroVysion relatively unfavorable.…”

Section: Main Body Molecular Markers As a Diagnostic Toolmentioning

confidence: 99%

What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?

Abdulmajed

Sancak

Reşorlu

et al. 2014

Turkish Journal of Urology

View full text Add to dashboard Cite

Urothelial carcinoma is the 9 th most common cancer worldwide. Most urothelial tumors are non-muscle invasive on presentation. However, two-thirds of non-invasive bladder cancers will eventually recur with a 25% risk of progression to muscle-invasive bladder cancer. Tumor stage, histological grade and pathological invasion of blood vessels and lymphatic tissue are the main indicators for urothelial cancer prognosis. The gold standard for diagnosing bladder cancer is conventional white-light cystoscopy and biopsy. Urine cytology is a highly specific, sensitive test for high-grade tumors or carcinoma in situ (CIS). Urinary NMP22 has an overall sensitivity and specificity for detecting bladder cancer of 49% and 87%, respectively. However, there are falsepositive results in the presence of urinary tract infection or hematuria. The detection of specific gene mutations related to urothelial cancers has been studied and employed to reproduce markers helpful for diagnosis. According to current studies, molecular markers can be used to predict tumor recurrence. From a prognostic point of view, new molecular markers have yet to be established as reliable indicators of tumor aggressiveness. We aimed to review the molecular markers with possible prognostic significance that have been discussed in the literature. This review examined the literature for various molecular markers under development for bladder cancer in an attempt to optimize patient care and reduce the costs of treating these patients.

show abstract

“…Several comparative studies have demonstrated that the sensitivity of FISH is superior to that of Cytology alone. [28][29][30] Epilogue According to published reports, the happy couple has settled into a mutually satisfying relationship, each helping to complete the other. The future holds additional opportunities for spousal collaboration: many genetic events, originally identified in hematologic and mesenchymal lesions, are being discovered in a variety of carcinomas as well, particularly salivary gland carcinomas.…”

Section: Bladder Cancermentioning

confidence: 99%

The marriage of Cytology and Cytogenetics

Cin¹,

Qian²,

Cibas³

2013

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

Use of a Multitarget Fluorescence In Situ Hybridization Assay to Diagnose Bladder Cancer in Patients With Hematuria

Cited by 107 publications

References 19 publications

Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology

Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology

What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?

The marriage of Cytology and Cytogenetics

Contact Info

Product

Resources

About